

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
WILMINGTON TRUST FSB		08/08/2011	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	DRUGTECH CORPORATION
Street Address:	300 Delaware Avenue, Suite 1270
City:	Wilmington
State/Country:	DELAWARE
Postal Code:	19801
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Serial Number:	77833035	DILITAZ
Registration Number:	3269576	INVEAMP
Registration Number:	1123580	MICRO-K
Serial Number:	77962857	NESHER
Serial Number:	85058278	N
Serial Number:	77962859	NESHER PHARMACEUTICALS
Registration Number:	2500706	NITROQUICK
Serial Number:	77833038	TIZEM

CORRESPONDENCE DATA

Fax Number: (314)345-7600
 Phone: 314-345-7000
 Email: kbastunas@senniger.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.
 Correspondent Name: Paul Fleischut- Senniger Powers LLP

OP \$215.00 77833035

Address Line 1: 100 North Broadway, 17th Floor
Address Line 4: St. Louis, MISSOURI 63102

ATTORNEY DOCKET NUMBER:	NSHP 9496
NAME OF SUBMITTER:	Paul I. J. Fleischut
Signature:	/paul fleischut/
Date:	10/21/2011

Total Attachments: 4
source=01613242#page1.tif
source=01613242#page2.tif
source=01613242#page3.tif
source=01613242#page4.tif

PARTIAL RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS PARTIAL RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Partial Release") is made as of August 8, 2011 (the "Effective Date") by Wilmington Trust, National Association (successor by merger to Wilmington Trust FSB), having a place of business at Rodney Square North, 1100 North Market Street, Wilmington, Delaware 19890, as collateral agent (in such capacity, together with its successors and permitted assigns, the "Agent") in favor of DrugTech Corporation, a Delaware corporation, located at One Corporate Woods Drive, Bridgeton, MO 63044 (the "Grantor"). The Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Indenture (as defined below), the Purchase Agreement (as defined below) or the Trademark Security Agreement (as defined below) as the case may be.

WHEREAS, reference is made to a (i) certain Indenture (the "Indenture"), dated as of March 17, 2011, by and among K-V Pharmaceutical Company, a Delaware corporation (the "Company"), the Agent, as Trustee, the Grantor and each of the other Guarantors named therein, and (ii) an Asset Purchase Agreement (the "Purchase Agreement"), dated as of June 17, 2011, by and among the Company, Neshor Pharmaceuticals Inc., Grantor, and Zydus Pharmaceuticals (USA), Inc. ("Zydus") and Zyneshor Pharmaceuticals (USA) LLC (together with Zydus, the "Buyer"), to sell the Purchased Assets (as defined in the Purchase Agreement) to the Buyer, which sale constitutes a sale of Designated Assets under the Indenture;

WHEREAS, pursuant to Section 9.05(b) of the Indenture, the Company has delivered to the Agent (i) an Officers' Certificate to the effect that all conditions precedent provided for in the Indenture and the Collateral Documents to the release of the security interest in the Purchased Assets have been complied with and requesting the release of the security interest; and (ii) an Opinion of Counsel to the effect that all conditions precedent provided for in the Indenture and the Collateral Documents to the release of the security interest in the Purchased Assets have been complied with;

WHEREAS, Grantor executed and delivered to the Agent that certain Trademark Security Agreement dated March 17, 2011 (the "Trademark Security Agreement") in favor of the Agent for the benefit of the Secured Parties as obligated in the Security Agreement referenced in the above defined Trademark Security Agreement;

WHEREAS, pursuant to the terms and conditions of the Trademark Security Agreement, Grantor pledged and granted to the Agent, to secure the obligations under the Security Agreement, a continuing security interest in all of such Grantor's right, title and interest in and to the Trademark Collateral (as defined in the Trademark Security Agreement);

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on March 18, 2011 at Reel/Frame 04501/0167; and

WHEREAS, the Company and the Grantor have requested that the Agent release its continuing security interest granted pursuant to the Trademark Security Agreement in and to the Trademark Collateral pertaining solely to those certain trademarks set forth on Schedule A hereto, which constitute a portion of the Purchased Assets (the "Released Trademark");

Collateral”). Upon Agent’s acceptance of the Letter for the “Release of Assets Sold to Zydus Pharmaceuticals (USA), Inc.” dated August 8, 2011, Agent agreed to release documents, including, without limitation, all releases in respect of the recordation of security interests in intellectual property, including Released Trademark Collateral, previously made by the Agent in the applicable intellectual property registries. Agent also will provide reasonable assistance, if requested by the Grantor or Company, to provide documentation to evidence to the termination and release of the liens and security interests in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent, on behalf of the Secured Parties and itself, hereby terminates, cancels and releases as of the Effective Date its continuing security interest granted in and to the Released Trademark Collateral pursuant to the Trademark Security Agreement and confirms that it no longer has any right, title and interest in and to the Released Trademark Collateral pursuant to the Trademark Security Agreement.

The release set forth herein shall be without recourse to or warranty by the Agent and shall relate solely to the Released Trademark Collateral.


THIS PARTIAL RELEASE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

* * * * *

IN WITNESS WHEREOF, the Agent has caused this Partial Release to be executed by its duly authorized representative as of the Effective Date.


GRANTOR:

DRUGTECH CORPORATION

By: 
Name: Thomas S. McHugh
Title: Treasurer and Vice President

COMPANY:


K-V PHARMACEUTICAL COMPANY

By: 
Name: Gregory J. Divis
Title: President and Chief Executive Officer

ACKNOWLEDGED AND AGREED BY:

AGENT:

WILMINGTON TRUST, NATIONAL ASSOCIATION,
As Collateral Agent

By: 
Name: Jane Schweiger
Title: Vice President

SCHEDULE A

(Reel/Frame 04501/0167)

Trademarks

Mark	Status	App. No.	Reg No.	Class	Ex-US Countries
DILITAZ	Allowed	77/833,035	-	5	None
INVEAMP	Registered	78/637,694	3,269,576	5	None
MICRO-K	Registered	73/179,777	1,123,580	5	Barbados Bermuda Canada Kuwait Nicaragua Paraguay South Africa Spain
NESHER	Allowed	77/962,857	-	5	None
NESHER "N" LOGO	Allowed	85/058,278	-	5	None
NESHER PHARMACEUTICALS	Allowed	77/962,859	-	5	None
TIZEM	Allowed	77/833,038	-	5	None
NITROQUICK	Registered	75/594,820	2,500,706	5	None